Literature DB >> 6822411

Effect of quinonyl-N-acetyl muramyl dipeptide on immune responses in tumor-bearing mice.

I Saiki, Y Tanio, K I Yamamoto, Y Yamamura, I Azuma.   

Abstract

The efficacy of 6-O-QS-10-N-acetyl muramyl-L-valyl-D-isoglutamine methyl ester (quinonyl-MDP-66) for restoring impaired immune status was examined in mice bearing Lewis lung carcinoma. Quinonyl-MDP-66 suspended in phosphate-buffered saline was shown to restore the depressed allogeneic cell-mediated cytotoxicity of spleen cells from mice with Lewis lung carcinoma when the chemical was injected twice intraperitoneally, intravenously, or intratumorally. However, primary tumor size and the numbers of lung metastases were not affected when quinonyl-MDP-66 was administered under the present experimental conditions. Intraperitoneal injection of quinonyl-MDP-66 in mice with Lewis lung carcinoma enhanced host resistance to Listeria monocytogenes infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6822411      PMCID: PMC347915          DOI: 10.1128/iai.39.1.137-141.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Novel quinonyl derivatives of muramyl dipeptide possessing potent antitumor activity.

Authors:  S Kobayashi; T Fukuda; I Imada; M Fujino; I Azuma; Y Yamamura
Journal:  Chem Pharm Bull (Tokyo)       Date:  1979-12       Impact factor: 1.645

2.  Alterations of host resistance to Listeria monocytogenes in tumour-bearing mice and the effect of Corynebacterium parvum.

Authors:  H Miyata; K Himeno; S Miake; K Nomoto
Journal:  Immunology       Date:  1981-10       Impact factor: 7.397

3.  In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes.

Authors:  S Sone; I J Fidler
Journal:  Cell Immunol       Date:  1981-01-01       Impact factor: 4.868

4.  Adjuvant activities of quinonyl-N-acetyl muramyl dipeptides in mice and guinea pigs.

Authors:  I Saiki; Y Tanio; M Yamawaki; M Uemiya; S Kobayashi; T Fukuda; H Yukimasa; Y Yamamura; I Azuma
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

5.  Role of NK cells in tumour growth and metastasis in beige mice.

Authors:  J E Talmadge; K M Meyers; D J Prieur; J R Starkey
Journal:  Nature       Date:  1980-04-17       Impact factor: 49.962

6.  Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines.

Authors:  I J Fidler
Journal:  Science       Date:  1980-06-27       Impact factor: 47.728

7.  Inhibition of experimental tumor metastasis by selective activation of natural killer cells.

Authors:  N Hanna
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

8.  Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.

Authors:  I J Fidler; S Sone; W E Fogler; Z L Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

9.  Role of natural killer cells in the destruction of circulating tumor emboli.

Authors:  N Hanna; I J Fidler
Journal:  J Natl Cancer Inst       Date:  1980-10       Impact factor: 13.506

10.  Immunosuppression in a murine B cell leukemia (BCL1): role of an adherent cell in the suppression of primary in vitro antibody responses.

Authors:  S A Anderson; P C Isakson; E Puré; M Muirhead; J W Uhr; E S Vitetta
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

View more
  4 in total

Review 1.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

2.  Monoclonal antibodies to Lewis lung carcinoma.

Authors:  S Ukei; I Saiki; I Azuma
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

3.  Activation of macrophages by quinonyl-N-acetylmuramyl dipeptide.

Authors:  I Saiki; Y Tokushima; K Nishimura; Y Yamamura; I Azuma
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

Review 4.  Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Authors:  Sanja Nabergoj; Irena Mlinarič-Raščan; Žiga Jakopin
Journal:  Med Res Rev       Date:  2018-12-13       Impact factor: 12.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.